Ken Fisher's BIO Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 118,683 shares of Bio-Rad Laboratories, Inc. (BIO) worth $33.08 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in BIO, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 36,755 shares. Largest reduction occurred in Q1 2023, reducing 48,629 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -12,411 | Reduce 9.47% | 118,683 | $278.75 |
| Q4 2025 | -2,371 | Reduce 1.78% | 131,094 | $302.99 |
| Q3 2025 | -4,277 | Reduce 3.11% | 133,465 | $280.39 |
| Q2 2025 | -5,884 | Reduce 4.10% | 137,742 | $241.32 |
| Q1 2025 | +36,755 | Add 34.39% | 143,626 | $243.56 |
| Q4 2024 | +14,135 | Add 15.24% | 106,871 | $328.51 |
| Q3 2024 | -886 | Reduce 0.95% | 92,736 | $334.58 |
| Q2 2024 | +12,679 | Add 15.66% | 93,622 | $273.11 |
| Q1 2024 | +279 | Add 0.35% | 80,943 | $345.87 |
| Q4 2023 | -14,244 | Reduce 15.01% | 80,664 | $322.89 |
| Q3 2023 | -1,223 | Reduce 1.27% | 94,908 | $358.45 |
| Q2 2023 | +238 | Add 0.25% | 96,131 | $379.12 |
| Q1 2023 | -48,629 | Reduce 33.65% | 95,893 | $479.02 |
| Q4 2022 | -3,597 | Reduce 2.43% | 144,522 | $420.49 |
| Q3 2022 | -2,139 | Reduce 1.42% | 148,119 | $417.14 |
| Q2 2022 | +10,258 | Add 7.33% | 150,258 | $495.00 |
| Q1 2022 | -24 | Reduce 0.02% | 140,000 | $563.23 |
| Q4 2021 | -5,791 | Reduce 3.97% | 140,024 | $755.57 |
| Q3 2021 | -2,337 | Reduce 1.58% | 145,815 | $745.95 |
| Q2 2021 | -9,227 | Reduce 5.86% | 148,152 | $644.29 |
| Q1 2021 | -7,320 | Reduce 4.44% | 157,379 | $571.17 |
| Q4 2020 | -2,703 | Reduce 1.61% | 164,699 | $582.94 |
| Q3 2020 | -28,369 | Reduce 14.49% | 167,402 | $515.46 |
| Q2 2020 | -15,373 | Reduce 7.28% | 195,771 | $451.49 |
| Q1 2020 | -13,499 | Reduce 6.01% | 211,144 | $350.56 |
| Q4 2019 | -26,561 | Reduce 10.57% | 224,643 | $370.03 |
| Q3 2019 | +11,462 | Add 4.78% | 251,204 | $332.74 |
| Q2 2019 | -5,773 | Reduce 2.35% | 239,742 | $312.59 |
| Q1 2019 | -13,280 | Reduce 5.13% | 245,515 | $305.68 |
| Q4 2018 | +2,443 | Add 0.95% | 258,795 | $232.22 |
| Q3 2018 | -6,345 | Reduce 2.42% | 256,352 | $312.99 |
| Q2 2018 | -2,375 | Reduce 0.90% | 262,697 | $288.54 |
| Q1 2018 | -10,105 | Reduce 3.67% | 265,072 | $250.08 |
| Q4 2017 | -2,264 | Reduce 0.82% | 275,177 | $238.67 |
| Q3 2017 | -2,148 | Reduce 0.77% | 277,441 | $222.22 |
| Q2 2017 | +5,233 | Add 1.91% | 279,589 | $226.31 |
| Q1 2017 | -9,269 | Reduce 3.27% | 274,356 | $199.34 |
| Q4 2016 | -6,791 | Reduce 2.34% | 283,625 | $182.28 |
| Q3 2016 | +8,833 | Add 3.14% | 290,416 | $163.81 |
| Q2 2016 | +12,508 | Add 4.65% | 281,583 | $143.92 |
| Q1 2016 | -5,559 | Reduce 2.02% | 269,075 | $140.18 |
| Q4 2015 | -885 | Reduce 0.32% | 274,634 | $138.66 |
| Q3 2015 | -10,697 | Reduce 3.74% | 275,519 | $134.31 |
| Q2 2015 | -2,285 | Reduce 0.79% | 286,216 | $150.61 |
| Q1 2015 | -1,675 | Reduce 0.58% | 288,501 | $135.18 |
| Q4 2014 | -2,995 | Reduce 1.02% | 290,176 | $120.56 |
| Q3 2014 | -1,570 | Reduce 0.53% | 293,171 | $113.40 |
| Q2 2014 | -42,400 | Reduce 12.58% | 294,741 | $119.71 |
| Q1 2014 | -5,075 | Reduce 1.48% | 337,141 | $128.12 |
| Q4 2013 | -10,705 | Reduce 3.03% | 342,216 | $123.61 |
| Q3 2013 | -935 | Reduce 0.26% | 352,921 | $117.56 |
| Q2 2013 | +353,856 | Add 0.00% | 353,856 | $112.20 |
Ken Fisher's Bio-Rad Laboratories Investment FAQs
Ken Fisher first purchased Bio-Rad Laboratories, Inc. (BIO) in Q2 2013, acquiring 353,856 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Bio-Rad Laboratories, Inc. (BIO) for 52 quarters since Q2 2013.
Ken Fisher's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q2 2013, adding 353,856 shares worth $39.7 M.
According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 118,683 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $33.08 M.
As of the Q1 2026 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 353,856 shares, as reported at the end of Q2 2013.